Brokerages predict that SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) will report sales of $25.11 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for SI-BONE’s earnings, with the lowest sales estimate coming in at $24.42 million and the highest estimate coming in at $25.79 million. SI-BONE reported sales of […]
SI-BONE (NASDAQ:SIBN – Get Rating)‘s stock had its “buy” rating restated by stock analysts at JMP Securities in a research report issued on Wednesday, TipRanks reports. They presently have a $36.00 price target on the stock. JMP Securities’ price objective suggests a potential upside of 149.13% from the company’s previous close. SIBN has been the […]
SI-BONE (NASDAQ:SIBN – Get Rating) and Embecta (NASDAQ:EMBC – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk. Profitability This table compares SI-BONE and Embecta’s net margins, return on […]
Shares of SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 12 month target price among […]